|
|
Blood, 1 July 2008, Vol. 112, No. 1, pp. 159-168.
Prepublished online as a Blood First Edition Paper on April 24, 2008; DOI 10.1182/blood-2007-11-124164.
 Previous Article | Next Article 
Submitted November 14, 2007
Accepted March 27, 2008
Role of decorin in the antimyeloma effects of osteoblasts
Xin Li, Angela Pennisi, and Shmuel Yaccoby*
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, United States
* Corresponding author; email: yaccobyshmuel{at}uams.edu.
Building on our previous report that osteoblasts and increased bone formation have a negative impact on myeloma cell growth in a subset of patients, we investigated the role of decorin, the main small leucine-rich proteoglycan (SLRP) expressed and produced by osteoblasts, in the antimyeloma effects of osteoblasts. In coculture experiments with osteoblasts, primary myeloma cell survival was significantly higher when decorin expression in osteoblasts was knocked down by short-hairpin RNA. Coculture experiments of myeloma cells and supporting osteoclasts in the presence of osteoblast-conditioned medium showed reduced myeloma cell survival, an effect that was attenuated by decorin-neutralizing antibody. Decorin overexpression in mesenchymal stem cells or use of recombinant decorin in coculture with osteoclasts reduced the ability of osteoclasts to support primary myeloma cell survival. The antimyeloma effect of decorin involved direct induction of apoptosis and activation of p21WAF. Decorin also inhibited myeloma cell-induced tube formation and osteoclast differentiation. Decorin expression was insignificantly lower in patients' than donors' osteoblasts and slightly increased by bortezomib. We conclude that certain SLRPs are involved in the antimyeloma effect of osteoblasts directly and indirectly through inhibition of angiogenesis and osteoclastogenesis; therefore, increasing endogenous or exogenous SLRPs in myelomatous bone may help control myeloma.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Pennisi, W. Ling, X. Li, S. Khan, J. D. Shaughnessy Jr, B. Barlogie, and S. Yaccoby
The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
Blood,
August 27, 2009;
114(9):
1803 - 1812.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Fulciniti, P. Tassone, T. Hideshima, S. Vallet, P. Nanjappa, S. A. Ettenberg, Z. Shen, N. Patel, Y.-t. Tai, D. Chauhan, et al.
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
Blood,
July 9, 2009;
114(2):
371 - 379.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Goldoni, A. Humphries, A. Nystrom, S. Sattar, R. T. Owens, D. J. McQuillan, K. Ireton, and R. V. Iozzo
Decorin is a novel antagonistic ligand of the Met receptor
J. Cell Biol.,
May 18, 2009;
185(4):
743 - 754.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
